4 projets européens trouvés
Recherche sur 125080 projets européens
TERMINÉ
Recognising Adverse Drug Reactions (WEB-RADR)
Date du début: 1 sept. 2014, Date de fin: 31 août 2017,
WEB-RADR is a consortium of leading experts in pharmacovigilance from regulatory agencies, research, academia and patient support groups. Together with EFPIA partners our aims will be to set policy & guidance and deliver robust information technology tools to address the potential for the reporting of adverse drug reactions (ADRs) through mobile applications and the recognition of drug safety sign ...
Voir le projet
20
Participants partenaires
TERMINÉ
Scalable, Standard based Interoperability Framework for Sustainable Pro-active Post Market Safety Studies (SALUS)
Date du début: 1 févr. 2012, Date de fin: 30 avr. 2015,
Pre-approval clinical trials cannot possibly ensure that a drug will not have disastrous side effects once it arrives on the market. Post-approval safety data gathering was put in place to address this problem, but as implemented, it has not proven to be as effective as hoped. This is due to the fact that, current post market safety studies largely depend on the submission of spontaneous case repo ...
Voir le projet
10
Participants partenaires
TERMINÉ
Pharmacoepidemiolocal Research on Outcomes of Therapeutics by a European ConsorTium (PROTECT)
Date du début: 1 sept. 2009, Date de fin: 30 avr. 2015,
Recent pharmacovigilance (PV) issues have led to questions regarding the ability of the current PV system to meet the global needs. Controversies around the assessment of spontaneous reports and conflicting results from pharmacoepidemiology studies may lead to delay in, or inappropriate, regulatory decisions. The PROTECT consortium, consisting of 20 core partners lead by the European Medicines Age ...
Voir le projet
36
Participants partenaires
TERMINÉ
Optimizing drug safety monitoring to enhance patient safety and achieve better health outcomes (Monitoring medicines)
Date du début: 1 sept. 2009, Date de fin: 31 juil. 2013,
"Medicines are one of the most common health interventions. Expenditure on pharmaceuticals range from 10–20 % of all health expenditure in rich countries & from 20–60 % in poor countries. Knowledge of appropriate & safe medicines has grown. But the incidence of medicines adverse effects remains high. In a UK study 6.5% of hospitals admissions were related to an adverse drug reaction (ADR). And as ...
Voir le projet